Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

This study tests whether a drug called Diamyd® (GAD-alum) can safely slow or prevent the development of type 1 diabetes in children and teenagers who carry certain genetic risk factors and show early signs that their immune system may be attacking their pancreas. **You may be eligible if...** - You are between 8 and 17 years old - You carry the HLA DR3-DQ2 genetic marker (a gene linked to higher type 1 diabetes risk) - You have tested positive for GADA antibodies and at least one other diabetes-related autoantibody - You do not yet have a diagnosis of type 1 diabetes - Your blood sugar and HbA1c levels are in the normal range **You may NOT be eligible if...** - You have already been diagnosed with type 1 diabetes - You are currently taking insulin or any anti-diabetic medication - You have used immune-suppressing medications in the past year - You are enrolled in another clinical drug trial - You have a history of epilepsy, serious head trauma, or hyperparathyroidism Talk to your doctor to see if this trial is right for you.